PTCT Stock - PTC Therapeutics, Inc.
Unlock GoAI Insights for PTCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $806.78M | $937.82M | $698.80M | $538.59M | $380.77M |
| Gross Profit | $749.38M | $872.34M | $654.12M | $506.26M | $361.82M |
| Gross Margin | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% |
| Operating Income | $-302,570,000 | $-439,502,000 | $-447,409,000 | $-374,443,000 | $-431,768,000 |
| Net Income | $-363,295,000 | $-626,604,000 | $-559,017,000 | $-523,901,000 | $-438,160,000 |
| Net Margin | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% |
| EPS | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Visit WebsiteEarnings History & Surprises
PTCTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.94 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-1.19 | $0.20 | +116.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.07 | $-0.83 | +22.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.08 | $10.04 | +1029.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.12 | $-0.24 | +78.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.54 | $-1.39 | +9.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.00 | $-1.16 | -16.0% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $-1.21 | $-1.20 | +0.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.29 | $-0.24 | -182.8% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-0.85 | $-1.76 | -107.1% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.58 | $-2.66 | -68.4% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-1.64 | $-1.88 | -14.6% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-1.96 | $-2.35 | -19.9% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-1.37 | $-1.53 | -11.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.67 | $-2.13 | -27.5% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-1.55 | $-1.78 | -14.8% | ✗ MISS |
Q1 2022 | Feb 22, 2022 | $-1.79 | $-2.03 | -13.4% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-1.78 | $-1.89 | -6.2% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-1.84 | $-1.68 | +8.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about PTCT
What is PTCT's current stock price?
What is the analyst price target for PTCT?
What sector is PTC Therapeutics, Inc. in?
What is PTCT's market cap?
Does PTCT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PTCT for comparison